Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Decreasing Late Mortality in Children with Leukemia
Biol Blood Marrow Transplant; ePub 2017 May 17; Bitan, et al
Intervening earlier in children with acute leukemia who are at risk for late mortality after allogeneic transplant may decrease the risk for some, according to a study involving nearly 1,900 individuals.
Participants included children with acute myeloid (AML; n=790) or acute lymphoblastic leukemia (ALL; n=1,096) who received transplantation between 2000 and 2010. Investigators looked at how acute and chronic graft versus host disease (GVHD) factors impacted leukemia-free and overall survival. Among the results:
- There were no prognostic factors beyond 4 years post-transplant for AML, or 3 years for ALL.
- Risk score for AML survival included age, disease status at transplantation, cytogenetic risk group, and chronic GVHD.
- Risk score for ALL survival included age at transplantation and chronic GVHD.
- The 10-year probability of overall survival for AML with good risk was 94%; for intermediate and poor risk, probabilities were 87% and 68%, respectively.
- The 10-year probabilities of overall survival for ALL with good and poor risk were 89% and 80%, respectively.
Bitan M, Woo Ahn K, Millard H, et al. Personalized prognostic risk score for long-term survival for children with acute leukemia after allogeneic transplant. [Published online ahead of print May 17, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.05.011.